Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation

被引:12
作者
Fazavana, Judicael [1 ]
Brophy, Teresa M. [1 ]
Chion, Alain [1 ]
Cooke, Niamh [2 ]
Terraube, Virginie [2 ]
Cohen, Justin [3 ]
Parng, Chuenlei [3 ]
Pittman, Debra [4 ]
Cunningham, Orla [2 ]
Lambert, Matthew [2 ]
O'Donnell, James S. [1 ,5 ]
O'Sullivan, Jamie M. [1 ]
机构
[1] Royal Coll Surgeons Ireland, Irish Ctr Vasc Biol, Sch Pharm & Biomol Sci, Dublin, Ireland
[2] Pfizer, BioMed Design, Dublin, Ireland
[3] Pfizer, BioMed Design, Cambridge, MA USA
[4] Pfizer, Rare Dis Res Unit, Cambridge, MA USA
[5] St James Hosp, Natl Coagulat Ctr, Dublin, Ireland
关键词
clearance; glycosylation; low density lipoprotein receptor-related protein; PEGylation; von Willebrand factor; VON-WILLEBRAND-FACTOR; FACTOR-VIII; PHENOTYPE; SURVIVAL; INSIGHTS;
D O I
10.1111/jth.14785
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Previous studies have demonstrated that the A1A2A3 domains of von Willebrand factor (VWF) play a key role in regulating macrophage-mediated clearance in vivo. In particular, the A1-domain has been shown to modulate interaction with macrophage low-density lipoprotein receptor-related protein-1 (LRP1) clearance receptor. Furthermore, N-linked glycans within the A2-domain have been shown to protect VWF against premature LRP1-mediated clearance. Importantly, however, the specific regions within A1A2A3 that enable macrophage binding have not been defined. Objective and Methods To address this, we utilized site-directed PEGylation and introduced novel targeted N-linked glycosylation within A1A2A3-VWF and subsequently examined VWF clearance. Results Conjugation with a 40-kDa polyethylene glycol (PEG) moiety significantly extended the half-life of A1A2A3-VWF in VWF-/- mice in a site-specific manner. For example, PEGylation at specific sites within the A1-domain (S1286) and A3-domain (V1803, S1807) attenuated VWF clearance in vivo, compared to wild-type A1A2A3-VWF. Furthermore, PEGylation at these specific sites ablated binding to differentiated THP-1 macrophages and LRP1 cluster II and cluster IV in-vitro. Conversely, PEGylation at other positions (Q1353-A1-domain and M1545-A2-domain) had limited effects on VWF clearance or binding to LRP1.Novel N-linked glycan chains were introduced at N1803 and N1807 in the A3-domain. In contrast to PEGylation at these sites, no significant extension in half-life was observed with these N-glycan variants. Conclusions These novel data demonstrate that site specific PEGylation but not site specific N-glycosylation modifies LRP1-dependent uptake of the A1A2A3-VWF by macrophages. This suggests that PEGylation, within the A1- and A3-domains in particular, may be used to attenuate LRP1-mediated clearance of VWF.
引用
收藏
页码:1278 / 1290
页数:13
相关论文
共 31 条
[1]   The von Willebrand factor A3 domain does not contain a metal ion-dependent adhesion site motif [J].
Bienkowska, J ;
Cruz, M ;
Atiemo, A ;
Handin, R ;
Liddington, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) :25162-25167
[2]   Clearance of von Willebrand factor [J].
Casari, C. ;
Lenting, P. J. ;
Wohner, N. ;
Christophe, O. D. ;
Denis, C. V. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 :202-211
[3]   Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia [J].
Casonato, Alessandra ;
Gallinaro, Lisa ;
Cattini, Maria Grazia ;
Pontara, Elena ;
Padrini, Roberto ;
Bertomoro, Antonella ;
Daidone, Viviana ;
Pagnan, Antonio .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (08) :1366-1372
[4]   Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD [J].
Castaman, Giancarlo ;
Lethagen, Stefan ;
Federici, Augusto B. ;
Tosetto, Alberto ;
Goodeve, Anne ;
Budde, Ulrich ;
Batlle, Javier ;
Meyer, Dominique ;
Mazurier, Claudine ;
Fressinaud, Edith ;
Goudemand, Jenny ;
Eikenboom, Jeroen ;
Schneppenheim, Reinhard ;
Ingerslev, Jorgen ;
Vorlova, Zdena ;
Habart, David ;
Holmberg, Lars ;
Pasi, John ;
Hill, Frank ;
Peake, Ian ;
Rodeghiero, Francesco .
BLOOD, 2008, 111 (07) :3531-3539
[5]   N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance [J].
Chion, Alain ;
O'Sullivan, Jamie M. ;
Drakeford, Clive ;
Bergsson, Gudmundur ;
Dalton, Niall ;
Aguila, Sonia ;
Ward, Soracha ;
Fallon, Padraic G. ;
Brophy, Teresa M. ;
Preston, Roger J. S. ;
Brady, Lauren ;
Sheils, Orla ;
Laffan, Michael ;
McKinnon, Thomas A. J. ;
O'Donnell, James S. .
BLOOD, 2016, 128 (15) :1959-1968
[6]  
Davies JA, 2008, J THROMB HAEMOST, V6, P97
[7]   VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease [J].
Eikenboom, Jeroen ;
Federici, Augusto B. ;
Dirven, Richard J. ;
Castaman, Giancarlo ;
Rodeghiero, Francesco ;
Budde, Ulrich ;
Schneppenheim, Reinhard ;
Batlle, Javier ;
Canciani, Maria Teresa ;
Goudemand, Jenny ;
Peake, Ian ;
Goodeve, Anne .
BLOOD, 2013, 121 (12) :2336-2339
[8]   Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib [J].
Emsley, J ;
Cruz, M ;
Handin, R ;
Liddington, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (17) :10396-10401
[9]   Elevated factor VIII levels and risk of venous thrombosis [J].
Jenkins, P. Vince ;
Rawley, Orla ;
Smith, Owen P. ;
O'Donnell, James S. .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (06) :653-663
[10]   Significant gynecological bleeding in women with low von Willebrand factor levels [J].
Lavin, Michelle ;
Aguila, Sonia ;
Dalton, Niall ;
Nolan, Margaret ;
Byrne, Mary ;
Ryan, Kevin ;
White, Barry ;
O'Connell, Niamh M. ;
O'Sullivan, Jamie M. ;
Di Paola, Jorge ;
James, Paula D. ;
O'Donnell, James S. .
BLOOD ADVANCES, 2018, 2 (14) :1784-1791